วัน: 23 กันยายน 2025

Highlights:Anson Resources (via its 100% owned subsidiary A1 Lithium) and LG Energy Solution have executed a Definitive Offtake Agreement ("Definitive Offtake Agreement") for the supply of battery grade lithium carbonate from Anson Resources' 100% owned Project within the Paradox Basin.Subject to the satisfaction of customary conditions precedent (summarised in the annexure), the Initial 5-year term is expected to commence in 2028, with the ability to extend for a further five years.LG Energy Solution to purchase 4,000 dry metric tonnes per year and specifies the operational and logistical requirements for the delivery of product.Pricing is determined using a formula-based mechanism referencing market prices for battery-grade Lithium Carbonate.LG Energy Solution is a leading global manufacturer of lithium-ion batteries for electric vehicles, mobility, IT, and energy storage systems.NEWPORT BEACH, CA, Sept 24, 2025 - (ACN Newswire via SeaPRwire.com) - Anson Resources Limited (ASX:ASN) ("Anson Resources" or "the Company") is pleased to announce that it has completed negotiations with LG Energy Solution and on the Definitive Offtake Agreement for the supply of battery-grade Lithium Carbonate from its 100% owned Project within the Paradox Basin in Southern Utah.The Definitive Offtake Agreement provides for the supply of up to 4,000 dry metric tonnes per annum (tpa) of battery-grade Lithium Carbonate produced at the Project, expected to commence in 2028, representing approximately 40% of the Project start-up production capacity of ~10,000tpa.LG Energy Solution is an ideal partner for Anson Resources with its diversified customer base of tier one OEMs and energy storage solutions (ESS) and strong investment to expanding production in North America. LG Energy Solution has eight facilities currently operating or under construction in North America, with stand-alone facilities in Michigan and Arizona and five joint venture facilities with major automakers.Signing of the Definitive Offtake Agreement with LG Energy Solution marks another key milestone for the Company's develops in the Paradox Basin. This Definitive Offtake Agreement will become effective subject to Anson Resources commencement of commercial production in the Paradox Basin and offtake product qualification with LG Energy Solution.The Paradox Basin is a globally significant lithium asset, which the Company through its 100% owned USA subsidiary A1 Lithium, is working to develop into one of the largest lithium resources in the United States. The Company is conducting exploration and test work of the brine, that is known to exist, across multiple areas in the Paradox formation. This work is on-going and if successful will support the Company's theory that the brines of the Paradox Basin contain one of the largest lithium resources in North America.This Definitive Offtake Agreement is also an essential part of the critical path for debt funding at the Final Investment Decision stage.Anson Resources Executive Chairman and Managing Director Bruce Richardson commented:"Anson is delighted to have concluded our definitive offtake agreement with LG Energy Solution for at least 40% of our production. LG Energy Solution not only has a diversified customer base of tier one OEM's they also have many energy storage solutions (ESS) customers.Anson recognized the unstoppable paradigm shift in the US supply chain for electric vehicle battery materials and ESS and the key role that Korean battery manufacturers are playing.This shift in manufacturing investment has led to an increased demand for lithium produced in the US, not only to shorten supply chains geographically but also increase US content of electric vehicle batteries and electric vehicles,Anson identified this change, targeted its offtake marketing activities to the companies that have made these investments into North America and in particular, the US where Anson development work in the Paradox Basin in Southern Utah is strategically positioned.This definitive offtake agreement establishes the foundation for a long-term partnership and we are proud that we will be supplying low cost US made lithium from the Paradox Basin to LG Energy Solution a leading global manufacturer of lithium-ion batteries for electric vehicles, mobility, IT, and energy storage systems."About Anson Resources LtdAnson Resources (ASX:ASN) is an ASX-listed mineral resources company with a portfolio of minerals projects in key demand-driven commodities. Its core asset is the Paradox Lithium Project in Utah, in the USA. Anson is focused on developing the Paradox Project into a significant lithium producing operation. The Company's goal is to create long-term shareholder value through the discovery, acquisition and development of natural resources that meet the demand of tomorrow's new energy and technology markets.www.ansonresources.com Follow us on Twitter @anson_irForward Looking Statements: Statements regarding plans with respect to Anson's mineral projects are forward looking statements. There can be no assurance that Anson's plans for development of its projects will proceed as expected and there can be no assurance that Anson will be able to confirm the presence of mineral deposits, that mineralisation may prove to be economic or that a project will be developed.Competent Person's Statement 1: The information in this announcement that relates to exploration results and geology is based on information compiled and/or reviewed by Mr Greg Knox, a member in good standing of the Australasian Institute of Mining and Metallurgy. Mr Knox is a geologist who has sufficient experience which is relevant to the style of mineralisation under consideration and to the activity being undertaken to qualify as a "Competent Person", as defined in the 2012 Edition of the Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves and consents to the inclusion in this report of the matters based on information in the form and context in which they appear. Mr Knox is a director of Anson.SOURCE: Anson Resources Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MOSINA, POLAND AND WEST PALM BEACH, FL, Sept 23, 2025 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the XV Federation of International Polo (FIP) European Polo Championship, held from August 26 to September 7 at the prestigious Sowiniec Polo Club in Mosina, Poland. The sports brand served for the fifth time as the Official Apparel Partner of this prestigious event, which is played every two years.XV Federation of International Polo European Polo Championship WinnersU.S. Polo Assn. outfitted players and umpires in custom-designed performance jerseys and branded caps, alongside field signage and branded on-site activations for event attendees, bringing the brand's authenticity and sport-inspired style to the tournament. The sports brand is the Official Apparel Partner of FIP, which the International Olympic Committee recognizes to host international polo competitions.Eight teams competed throughout the XV FIP European Polo Championship, and the thrilling final game concluded with Spain taking the coveted European title in a hard-fought victory over Switzerland, with a final score of 7.5 - 4. This is the second consecutive win for Spain in the FIP European Polo Championship. The team also won the XII FIP World Polo Championship in 2022, hosted at the USPA National Polo Center (NPC) in Wellington, Florida."U.S. Polo Assn.'s support of the XV Federation of International Polo European Polo Championship as the Official Apparel Partner exemplifies everything we stand for as a global sports brand," said J. Michael Prince, CEO and President of USPA Global, the company that manages the global, multi-billion-dollar U.S. Polo Assn. brand. "We are honored to be part of such an important international sporting moment, especially as the XV European Polo Championship arrived in Poland for the first time in history.""We are also planning to bring the U.S. Polo Assn. brand to Poland in early 2026 for consumers in the region to experience the sport-inspired brand," Prince added.In addition to U.S. Polo Assn., the XV FIP European Polo Championship featured many high-profile sponsors, including Vogue Poland, Royal Salute Scotch Whisky, Taittinger Champagne, Antonius Caviar, Defender, Plucinski 1906, and others, all contributing to the event's elevated and luxurious atmosphere at Sowiniec Polo Club."U.S. Polo Assn. has continued to be a standout partner to the Federation of International Polo for the past nine years, helping to elevate the visibility and professionalism of our most important tournaments," said Alex Taylor, Executive Board Member of FIP. "The brand's support has been instrumental in bringing the European Polo Championship to Poland, a country with a rich polo legacy and a growing community of athletes and sports fans."The XV FIP European Polo Championship, first held in 1993, brought a vibrant spotlight to Polish polo's century-old history, which dates back to 1911. Today, with nearly 100 active players and a growing interest, Poland served as an exciting new host for this major international sporting event.Photo Credit: Andrzej OlszanowskiAbout U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center (NPC) in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.About the Federation of International Polo (FIP)Recognized by the International Olympic Committee (IOC), the Federation of International Polo (FIP) is the global organization representing the sport of polo. FIP's mission is to promote, develop, and regulate the sport of polo internationally.Contact InformationStacey KovalskyVP, Global PR and Communicationsskovalsky@uspagl.com+001.561.790.8036Shannon StilsonVP, Sports Marketing and Mediasstilson@uspagl.com+001.561.227.6994SOURCE: U.S. Polo Assn. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BUSAN, SOUTH KOREA, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – “Hong Kong Cinema @ BUSAN 2025” – a promotional campaign jointly organised by the Cultural and Creative Industries Development Agency (CCIDA) of the Culture, Sports and Tourism Bureau (CSTB) of the Hong Kong SAR Government, the Hong Kong Film Development Council (FDC) and the Hong Kong Trade Development Council (HKTDC) – was held from 20 to 23 September at the Asian Contents & Film Market (ACFM) in Busan, South Korea.  The campaign included exhibitions and networking activities that helped promote Hong Kong film production, strengthening Hong Kong's position as an East-meets-West centre for international cultural exchange and as a regional intellectual property trading centre. Additionally, the campaign showcased the latest works from Hong Kong and provided a platform for local filmmakers to interact with international industry peers and explore collaboration opportunities.HKTDC Deputy Executive Director Patrick Lau stated: “We are pleased that the HKTDC co-organised ‘Hong Kong Cinema @ BUSAN 2025’ this year, teaming up once again with the local film industry to showcase the industry’s vitality and creativity to overseas counterparts. We aim to build an international exchange platform so local filmmakers can engage with their overseas peers, helping them understand the latest global market trends and gain crucial industry information in an ever-changing environment. Through flexible adaptation, filmmakers can explore new realms of innovation.”Hong Kong delegation deepens international industry exchangeA Hong Kong Night was held at the Paradise Hotel Busan on 19 September, marking the start of “Hong Kong Cinema @ BUSAN 2025”. The event drew over 600 industry professionals from Hong Kong and around the world, creating opportunities for future collaboration.Members of the Hong Kong delegation included Sylvia Chang, producer of Hong Kong film Measure in Love, director Siu-Ping Kung and actress Angela Yuen, as well as Hong Kong producers Johnny Wang, Terence Choi, Fanny Chong and Kinnie Cheung. Sylvia Chang was awarded the “Camellia Award” by the Busan International Film Festival, in recognition of her outstanding achievements as a female filmmaker.In addition to attending various exchange activities organised by the Hong Kong side, Hong Kong producers participated in official ACFM events, such as the Producer Hub. These events also included luncheons, panel discussions and networking sessions, strengthening connections with overseas producers and production companies, while creating opportunities to explore cross-border collaboration.Exhibition and networking activities propel international cooperationA Hong Kong Pavilion, funded by the CCIDA and the Film Development Fund (FDF), was set up at the ACFM. Participating Hong Kong film production and distribution companies included Cappu Films Limited, Golden Network Asia Limited, Mei Ah Entertainment Group Ltd, One Cool Pictures Limited and Mandarin Motion Pictures Limited.Additionally, other visiting Hong Kong film companies and organisations included 32cc Limited, Edko Films Limited, Emperor Motion Pictures, Entertaining Power Co. Limited, Golden Scene Company Limited, the Asian Film Awards Academy and the Industry Office of the Hong Kong International Film Festival Society.The Hong Kong Pavilion also showcased Hong Kong films that had been selected for the 30th Busan International Film Festival. These included: The Shadow's Edge, in the Open Cinema section; Measure in Love, funded by the Directors’ Succession Scheme under the FDF, in the Open Cinema section; and Girlfriends, in the Vision - Asia section.Hong Kong and South Korea forge new path with MoU to strengthen collaboration in film talent developmentDuring the event, CCIDA signed a memorandum of understanding (MoU) with the Busan Asian Film School, with an aim to strengthen collaboration between Hong Kong and South Korea in activities and exchanges to nurture film talents.HTKDC shared market insightsRepresentatives from the HKTDC also attended the official summit of the ACFM, the Asian Film Market Leaders Summit. At the Summit, Josephine Lam, Section Head of HKTDC’s Entertainment Industry, Service Promotion Department, engaged in discussions with representatives from major Asian film markets, such as Busan’s ACFM, the Tokyo International Film Festival Content Market (TIFFCOM), the Taiwan Creative Content Fest (TCCF), the Jogja-NETPAC Asian Film Festival (JAFF Market) and the Red Sea Souk in Saudi Arabia. Ms Lam also shared insights from the Hong Kong International Film & TV Market (FILMART), highlighting its role as one of Asia's primary film markets.Several participating companies expressed satisfaction with “Hong Kong Cinema @ BUSAN 2025”, stating that the campaign successfully showcased the strengths of Hong Kong's film industry to overseas markets. They also noted that the campaign facilitated increased collaboration and exchange between Hong Kong filmmakers and their international counterparts.Photo download: http://bit.ly/3IDqJBRThe Hong Kong Pavilion, funded by the CCIDA and the FDF, is set up at the ACFMGuests attending Hong Kong Night included Sylvia Chang, producer of Hong Kong film Measure in LoveIrene Yuen (left), Head (Film Promotion and Facilitation) of the CCIDA, and Kang Sung Kui (right), Director of the Busan Asian Film School, signed a Memorandum of Understanding (MoU)Hong Kong producers Johnny Wang, Terence Choi, and Kinnie Cheung engaged in exchanges with international industry professionals at Producer Hub of the ACFMJosephine Lam, Section Head of HKTDC’s Entertainment Industry, Service Promotion Department, shared market insights at the Asian Film Market Leaders SummitMedia enquiriesHKTDC’s Communications & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395          Email: johnny.cy.tsui@hktdc.org  About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedInAbout CCIDACultural and Creative Industries Development Agency (CCIDA) (formerly known as Create Hong Kong) was set up in 2009 as a dedicated agency to lead, champion and drive the development of our creative industries.  It also serves as the secretariat of the CreateSmart Initiative and the Film Development Fund.To further promote the development of arts, culture and creative sectors as industries, the Government of the Hong Kong Special Administrative Region completed the restructuring of Create Hong Kong as CCIDA on 14 June 2024 pursuant to the 2023 Policy Address.  CCIDA is playing a more proactive and positive role to strengthen its support for the development of the arts, cultural and creative sectors, including identifying opportunities for the relevant industries and leading creative industries to arrange delegations to various showcases worldwide, thereby exporting Hong Kong’s cultural and creative industries including film, advertising, architecture, design, digital entertainment, music, printing and publishing, and television.About HKFDCIn his Policy Address in October 2006, the Chief Executive announced that the then Secretary for Commerce, Industry and Technology will co-ordinate the film-related policy, planning and activities, including manpower training, Mainland and overseas promotion, and filming support.  From 1 July 2022 onwards, the relevant work is co-ordinated by the Secretary for Culture, Sports and Tourism. In order to support the Secretary and to ensure the policy is in line with the sustainable development of the film industry, the Government established the Hong Kong Film Development Council (HKFDC) on 15 April 2007.The Film Development Fund (FDF) was first set up by the Government in 1999 to support projects conducive to the long-term development of the film industry in Hong Kong.  Since 2005, the Government has injected a total of about $2.9 billion into the FDF to support Hong Kong film industry along four strategic directions, namely nurturing talent, enhancing local production, expanding markets and building audience. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – Ta Yang Group Holdings Limited ("Ta Yang Group" or the "Group"; Stock Code: 1991.HK) is pleased to announce that, to seize the opportunities of Web 4.0 and further advance our AI and digital transformation strategy, the Group is currently considering a potential rights issue. The proposed fundraising would be used for the research and development (“R&D”) of AI digital human technologies, the establishment of real-world asset (“RWA”) profolilo and the framework for on-chain solutions, and the acquisition of strategic digital assets, such as cryptocurrencies like Ethereum (“ETH”) as reserves, all of which are aligned with the Group’s strategic transformation towards Web 4.0 and the buildout of the RWA ecosystem.This potential rights issue is expected to provide financial support for the strategic direction announced by the Group in August, supporting enterprises and institutions in their AI and digital transformation initiatives. This includes establishing a core digital asset pool, accelerating the R&D of AI digital human technologies, and deepening the RWA ecosystem. At the same time, the potential rights issue would bring in fresh capital and resources to strengthen the Group’s financial foundation, empowering the Group to capture long-term opportunities arising from the digital transformation of the trillion-dollar industries it targets: education, gaming, and healthcare.Chairlady of Ta Yang Group, Ms. Shi Qi commented: “The potential rights issue carries crucial positive significance for the Group as it advances into the new era of the digital economy. We are undergoing a transformation from capital innovation to technological innovation and ultimately to business model innovation, a process that complements the transformation blueprint we announced earlier. We believe this potential rights issue will enable us to seize a first-mover advantage in Web 4.0 development, accelerating our move towards RWA field and is expected to open up new revenue streams in future, including paid AI digital human services, digital human IP trading, and services of the RWA ecosystem. We are grateful for the continued support of our shareholders and are confident that this strategic move, aligned with our long-term plan, will generate substantial and sustainable returns for them.”About Ta Yang Group Holdings Ltd. (Stock Code: 1991.HK)Founded in 1991 and listed on the Hong Kong Stock Exchange in 2007, Ta Yang Group Holdings Limited (Stock code: 1991.HK) combines thirty years of industry expertise with forward-looking digital vision as a diversified enterprise. The Group initially focused on silicone input devices, designing and manufacturing core components for consumer electronics, computers, laptops, mobile phones, and automotive accessories. Leveraging integrated production systems, strict quality controls, and technological innovation, Ta Yang Group has earned the long-term trust of leading global brands and established a solid industrial foundation.With the acceleration of global digital transformation, Ta Yang Group keenly recognized strategic opportunities in the digital economy era and decisively launched a full-scale strategic transition to Web 4.0, adopting “embracing technological change, reconstructing value ecology” as its core direction, focusing on AI, RWA tokenization, and Hong Kong policy ecosystem as its three chief drivers. Committed to forging a “Data—Asset—Value” transfer chain, the Group is transitioning from traditional manufacturing to a leader in the digital economy.At present, Ta Yang Group is embracing Web 4.0 transformation as a new starting point, focusing on education, gaming, and healthcare as three trillion-dollar tracks, aiming to become a leading AI and RWA dual-sector player in Asia-Pacific, delivering highly efficient value-growth ecosystems to global investors, partners, and individuals, and continuously advancing the high-quality development of the global digital economy—writing a new page from ”industrial cultivator” to ”digital ecosystem builder”. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Sept 23, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the “Agreements”) with Chongqing Genrix Biopharmaceutical Co., Ltd. (“Genrix Bio”) for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, “Vecantoxatug”) indicated for passive immunization against tetanus and Silevimig Injection (GR1801, “Silevimig”) indicated for passive immunization following suspected rabies virus exposure, respectively. In accordance with the Agreements, the Group has obtained exclusive commercialization rights for these two products in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration terms respectively extend until ten years after these two products receive their marketing approvals in Mainland China (the “Initial Term for each Product”). Unless terminated or dissolved under the terms set forth in the Agreements, the Agreements will automatically renew for successive ten-year periods upon expiration of the Initial Term for each Product.Vecantoxatug is a passive immunization agent with an excellent safety profile, which delivers superior protection compared with human tetanus immunoglobulin (HTIG), providing rapid and durable immune defense for patients. Its Phase III clinical trial for passive immunization against tetanus successfully met the primary efficacy endpoint. In May 2024, Vecantoxatug was designated Breakthrough Therapy by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). On 22 May 2025, its New Drug Application (NDA) was formally accepted by the CDE.Silevimig is the world’s first recombinant, fully human bispecific antibody against rabies virus (RABV) targeting epitope I and/or epitope III of the rabies virus glycoprotein, developed in accordance with the World Health Organization (WHO) recommended “cocktail” therapeutic option targeting distinct antigenic sites. It can be manufactured at scale with standardized, and also demonstrates broad neutralization, low immunogenicity, minimal interference with vaccine-induced active immunity, and controlled production cost. On 14 January 2025, its NDA for use in adults requiring passive immunization following suspected rabies virus exposure was formally accepted by CDE. In addition, in July 2025, the NMPA approved the clinical trial application for Silevimig in children and adolescents aged 2 to <18 years requiring passive immunization following suspected rabies virus exposure. This Phase III clinical trial is currently in progress.CMS has always been committed to deploying innovative products with clinical value and differentiated advantages. The market for tetanus and rabies passive immunization remains substantial, yet existing passive immunization products are constrained by safety and accessibility concerns. If approved, Vecantoxatug and Silevimig will provide new preventive and therapeutic options of passive immunization for patients following tetanus and rabies exposure. Additionally, they will synergize with the Group’s existing products in expert networks and market resources, bringing benefit to patients.More information about Vecantoxatug and TetanusVecantoxatug is a recombinant humanized monoclonal antibody against tetanus neurotoxin (TeNT), which is self-developed by Genrix Bio. Vecantoxatug binds to the fragment C domain of the TeNT heavy chain (TeNT-Hc). TeNT is an about 150 kDa single-chain protein that undergoes post-translational modification to form an active toxin composed of heavy and light chains. By specifically binding TeNT-Hc, Vecantoxatug effectively blocks toxin entry into neurons, providing passive immunization. The patent for Vecantoxatug has been granted in China.Tetanus is an acute and specifical infection caused by Clostridium tetani (C. tetani) entering the body through wounds. It affects individuals across all age groups and, in the absence of medical intervention, is almost universally fatal-particularly among infants and the elderly. Even with active treatment, global mortality remains as high as 30-50%, with an estimated 500,000 to 1,000,000 cases reported annually worldwide[1].C. tetani is ubiquitous in soil and the environment, and is also present in the intestines of mammals. As the pathogen invades through skin or mucosal injuries, causing the acute and specifical infection, prevention remains the most effective strategy. Currently available passive immunization agents, commonly known as tetanus shot, - tetanus antitoxin (TAT), equine-derived tetanus immunoglobulin (F(ab’)2), and human tetanus immunoglobulin (HTIG) - face notable limitations in safety and accessibility[2], including risks of allergic reactions, potential infectious pathogen transmission, and limited availability. Consequently, there remains a pressing clinical need for new preventive and therapeutic options. Vecantoxatug is able to provide greater protection than HTIG, while demonstrating excellent safety, tolerability, and low immunogenicity. With enhanced controllability and accessibility, Vecantoxatug has the potential to offer patients an advanced preventive and therapeutic option.More information about Silevimig and RabiesSilevimig is a recombinant, fully human bispecific antibody against rabies virus, which is self-developed by Genrix Bio. It targets the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and/or III. Through this mechanism, Silevimig prevents RABV from invading neural tissue prior to the establishment of full protection by active rabies vaccination, thereby helping to prevent rabies infection. Silevimig’s molecular design is consistent with the recommendations of the WHO for anti-RABV antibody development, which emphasize the use of “cocktail” combinations of monoclonal antibodies targeting distinct antigenic sites to ensure broad effectiveness across different viral strains and genotypes. The patent for Silevimig has been granted in China.In a Phase III clinical trial for post-exposure passive immunization in adults, Silevimig met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with human rabies immunoglobulin (HRIG), the currently most used passive immunization product in China. The study confirmed that Silevimig provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination.Rabies is an acute zoonotic disease caused by RABV, clinically characterized by hydrophobia, aerophobia, pharyngeal muscle spasms, and progressive paralysis[3]. With a case-fatality rate approaching 100%, it is one of the deadliest diseases worldwide. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized Post-Exposure Prophylaxis (PEP), comprising wound care, vaccination, and passive immunization administered as needed, remains the most effective rabies prevention strategy[4]. As vaccine-induced antibodies require 1–2 weeks after the first dose of vaccine injection, to reach protective levels (≥0.5 IU/mL), passive immunization provides immediate coverage during this high-risk window[3]. According to the the National Regulation for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure and those with severe immunodeficiency and Category II exposure should receive passive immunization at the same time as the first dose of rabies vaccine[5]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% (16 million) fall under Category III exposure[3]. However, due to factors such as limited awareness, high cost, and restricted accessibility, only about 15% of Category III cases receive passive immunization[3].Currently approved passive immunization options in China include human rabies immunoglobulin (HRIG) and equine rabies antiserum (ERA), both of which provide immediate protection by preventing viral entry into neural tissue. HRIG must be sourced from repeatedly immunized healthy donors, making it difficult and costly to obtain. And it is associated with potential risks of blood-borne infections (e.g., HIV, hepatitis B, hepatitis C). ERA, being a heterologous protein, is prone to adverse reactions such as serum sickness and anaphylactic shock[3]. Beyond HRIG and ERA, only two rabies antibody products have been approved in China to date. Silevimig is the world’s first recombinant, fully human bispecific antibody for passive immunization against rabies, which is consistent with the WHO recommended “cocktail” approach. Its approval is expected to provide patients with broad and robust protection.About GENRIX BIOGenrix Bio (Stock Code: 688443), founded in 2015, is an innovative biopharmaceutical company driven by advanced antibody drug discovery technology to address critical clinical needs. Genrix Bio is committed to the development of monoclonal and bispecific antibodies for autoimmune diseases, infectious diseases, and oncology. Its capabilities span across antibody molecular discovery, process development and quality research, clinical trials, and large-scale commercialization. Learn more about Genrix Bio and its products at https://www.genrixbio.com/About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.Reference:1. China Trauma Rescue and Treatment Association. Peking University Trauma Medicine Center. Chinese expert consensus on tetanus immunization[J]. Chinese Journal of Surgery,2018,56(3):161-167. DOI: 10.3760/cma.j.issn.0529-5815.2018.03.0012. Members of the Emergency Surgery Committee of Chinese College of Emergency Physicians, Members of the Emergency Medicine Committee of the People's Liberation Army, Beijing Society for Emergency Medicine, et al. Expert consensus on prophylaxis, diagnosis and management of tetanus among adults[J]. Journal of Clinical Emergency, 2018, 19(12):801-811. DOI: 10.13201/j.issn.1009-5918.2018.12.0013. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf4. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis[J]. Chinese Journal of Preventive Medicine, 2019,53(7):668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.0045. Chinese Center for Disease Control and Prevention. The National Regulation for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdfCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – On September 16th, the "Industrial Intelligent Water Saving and Efficiency Promotion Event & GreenTech WateRobot AI Agent 1.0 Ecosystem Launch", hosted by the China Industrial Energy Conservation and Cleaner Production Association, GreenTech Environment Co., Ltd., and Beijing Zhenghe Island Information Technology Co., Ltd., was successfully convened in Beijing.Centered on the theme "AI for Water Freedom", the event brought together nearly 400 industry experts, research institutions, universities, environmental protection enterprises, and financial institutions to witness the launch of the WateRobot AI Agent and explore the new developments in water savings and efficiency brought by AI agents to the industry.(Launch event scene)Wang Xiaokang, President of the China Industrial Energy Conservation and Cleaner Production Association, attended and addressed the event, noting that AI empowerment will unlock new possibilities for environmental governance and industrial water conservation, and that the WateRobot AI Agent is an innovative achievement of deep integration between intelligence and water technology. Liu Donghua, Founder and Chief Architect of Zhenghe Island, delivered a speech proposing that the resource utilization of wastewater can find optimal solutions through AI, and that the widespread application and continuous upgrading of the WateRobot AI Agent can inject significant strength into achieving "Water Freedom" for industry, cities, and even the nation.The event invited AI expert Wei Kai, Director of the Artificial Intelligence Research Institute at the China Academy of Information and Communications Technology, to deliver a keynote speech on "Artificial Intelligence+ Policies and Industrial Practices". He pointed out that advancements in large language models have brought new paradigms to the development of AI technology, and the birth of the WateRobot AI Agent represents an important attempt of AI in the field of industrial water treatment.Subsequently, GreenTech officially launched the WateRobot AI Agent. Chairman Zhang Huichun proposed that using AI to replace human management of water plants can achieve industrial assembly line production, modular assembly, unmanned operation, and intelligent operation of water plants, replacing the traditional operational models of conventional engineered water plants. This leads to a 90% reduction in footprint, construction period, and operational staff, as well as a 50% reduction in Life Cycle Cost (LCC), ultimately enabling humanity to obtain Sustainable, Abundant, Reliable, and Affordable High-quality water (SARAH), achieving Water Freedom.(WateRobot AI Agent product interface)Wang Xiaoyu, General Manager of the Digital Technology Business Unit of GreenTech, further elaborated that the WateRobot AI Agent is an AI agent system capable of autonomous operation and completing target tasks. It not only incorporates GreenTech's self-developed process optimization forecasting and decision-making models but also integrates computer vision, auditory, infrared, and other perceptual AI models, as well as domestic large language inference models. Under the Online to Offline closed-loop logic, it directly delivers value to customers——safe, efficient, and optimally cost-operated unmanned water plants. The WateRobot AI Agent has already been applied in newater house water plant scenarios and is expected to expand to other water treatment plants, as well as industrial, agricultural, and municipal facilities, committed to enabling unmanned operation and innovative operational models across various fields.The event featured the unveiling ceremony of the "Artificial Intelligence Innovation Research Center" jointly established by GreenTech and Wuhan University. Zhang Liping, Deputy Director of the Industry-Academia-Research Cooperation Office of the Science and Technology Development Research Institute of Wuhan University, attended the unveiling and delivered a speech. Both parties will conduct in-depth technical research and industry applications focused on unmanned and intelligent operations. A roundtable dialogue on "AI + Industry" with the theme "AI's New Mission: Driving Industrial Restructuring and a Sustainable Future" was also held, where AI experts and various entrepreneurs discussed the application scenarios, value advantages, and future prospects of AI in the industrial field.GreenTech entered into strategic partnerships with the Finance Center for South-South Cooperation, Shanxi Xinzhou Economic Development Zone, CPIC Investment Management (H.K.), Wuhan Easy-Sight Technology Co.,Ltd., Green Technology (Shanghai) Agricultural Technology Co., Ltd., China Construction Eco-Development Co., Ltd., Beijing Boqi Electric Power Technology Co., Ltd., Beijing Zhenghe Island Information Technology Co., Ltd., and China Chemical Enterprise Management Association, among others, to jointly promote the application and promotion of the WateRobot AI Agent in the industry and various sectors domestically and internationally.The launch not only marked the debut of the WaterRobot AI Agent, a "new species" driving intelligent and green transformation in the industry but also envisioned the future of an intelligent water ecosystem——AI for Water Freedom. Through the innovative practices of GreenTech, the mission of "AI assisting industrial water savings and efficiency" has taken a solid step forward. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – Nissin Foods Company Limited (“Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is pleased to announce that the Group has entered into contracts for the land use rights of two strategically located parcels of land (the “Land Parcels”) in Zhuhai.Located in the Jinwan District of Zhuhai City, Guangdong Province, the Land Parcels were sold by the Zhuhai Natural Resources Bureau, a government authority responsible for managing land resources. The total consideration for the land is RMB30.68 million, covering a total land area of approximately 58,487 square meters. Nissin Foods plans to invest over RMB240 million to acquire the land, construct new facilities, and install cutting-edge automated production lines. Nissin Foods is committed to providing consumers with high-quality yet affordable food products. Incorporated with advanced automation and labour-saving technologies, the new factory will enhance production capacity and improve efficiency by reducing operational downtime. These initiatives are part of the Group’s commitment to sustainable growth, enabling it to respond flexibly to market changes and keep pace with growing consumer demand for the Group’s premium products. Strategically located in the Greater Bay Area, the new factory will create operational synergies with the current adjacent facilities of the Group.Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Despite global economic uncertainties, Mainland China’s consumer market maintained steady recovery in the first half of 2025, driven by a series of government policies aimed at stimulating consumption and expanding domestic demand. Consequently, the Group’s revenue in Mainland China rose by 9.4% to HK$1,221.9 million in the same period.“This land acquisition aligns perfectly with the company’s strategic goals and supports its ongoing growth. The new land and facilities will help maintain a steady supply of quality products while meeting the anticipated growth in sales. This is expected to inject new momentum into the Group’s operational development and long-term growth prospects, thereby enhancing its overall income and profitability.”For more information, please refer to the announcement on the Hong Kong Stock Exchange website: www1.hkexnews.hk/listedco/listconews/sehk/2025/0911/2025091100394.pdfAbout Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN ” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum ” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first-and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Food and Drink Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com